Break it Down: LTR Pharma flexes SPONTAN spray success

In this episode of Break it Down, host Fraser Palamara discusses important new study results for LTR Pharma’s SPONTAN nasal spray.

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Fraser Palamara explains why LTR Pharma (ASX:LTP) could shake up erectile dysfunction remedies.

The company shared news today its SPONTAN nasal spray treatment impressed in a bio-equivalence study - showing strong promise to disrupt the traditional PDE5 oral remedy market. The study demonstrated positive results in drug dosage and rate efficiency.

Tune in to get the latest.

While LTR Pharma is a Stockhead advertiser, it did not sponsor this content.

This content first appeared on stockhead.com.au

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox. Click here

Originally published as Break it Down: LTR Pharma flexes SPONTAN spray success